1. US Food and Drug Administration. Early consultation. In: Code of Federal Regulations Title 21. Washington, DC: US Government Printing Office; 2013. Pt 312.82.
2. US Food and Drug Administration. New drugs at FDA: CDER’s new molecular entities and new therapeutic biological products of 2014. http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/default.htm. Accessed February 21, 2014.
3. Sinicrope K, Zhou P. FDA approvals of new molecular entities for rare diseases: review of pre-IND meeting data from the Database Analysis Search Host (DASH). Paper presented at: National Organization for Rare Disorders Conference; Washington, DC; October 25, 2012.
4. Orphan Drug Act, Pub L 97–414. 96 Stat 2049 (1983). Amended in 1984 by Pub L 98–551 to add a numeric prevalence threshold to the definition of rare diseases.
5. US Food and Drug Administration. Filing an application and receiving an abbreviated new drug application. In: Code of Federal Regulations Title 21. Washington, DC: US Government Printing Office; 2013. Pt 314.101.